Trial Profile
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS or EGFR Mutation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 18 Jan 2023 Status changed from active, no longer recruiting to completed.
- 13 Apr 2022 Results assessing safety of binimetinib in combination with erlotinib in patients with NSCLC harboring KRAS or EGFR mutation, presented at the 113th Annual Meeting of the American Association for Cancer Research.
- 14 Mar 2022 Planned End Date changed from 30 Apr 2023 to 30 Dec 2022.